229 related articles for article (PubMed ID: 28157321)
1. Breast Cancer Targeting Peptide Binds Keratin 1: A New Molecular Marker for Targeted Drug Delivery to Breast Cancer.
Soudy R; Etayash H; Bahadorani K; Lavasanifar A; Kaur K
Mol Pharm; 2017 Mar; 14(3):593-604. PubMed ID: 28157321
[TBL] [Abstract][Full Text] [Related]
2. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
3. A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.
Song Q; Chuan X; Chen B; He B; Zhang H; Dai W; Wang X; Zhang Q
Drug Deliv; 2016 Jun; 23(5):1734-46. PubMed ID: 25853477
[TBL] [Abstract][Full Text] [Related]
4. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
[TBL] [Abstract][Full Text] [Related]
5. Synthetic peptides derived from the sequence of a lasso peptide microcin J25 show antibacterial activity.
Soudy R; Wang L; Kaur K
Bioorg Med Chem; 2012 Mar; 20(5):1794-800. PubMed ID: 22304849
[TBL] [Abstract][Full Text] [Related]
6. Peptide-Drug Conjugate Targeting Keratin 1 Inhibits Triple-Negative Breast Cancer in Mice.
Ziaei E; Paiva IM; Yao SJ; Sarrami N; Mehinrad P; Lai J; Lavasanifar A; Kaur K
Mol Pharm; 2023 Jul; 20(7):3570-3577. PubMed ID: 37307328
[TBL] [Abstract][Full Text] [Related]
7. Improved breast cancer cell-specific intracellular drug delivery and therapeutic efficacy by coupling decoration with cell penetrating peptide and SP90 peptide.
Fan LQ; Du GX; Li PF; Li MW; Sun Y; Zhao LM
Biomed Pharmacother; 2016 Dec; 84():1783-1791. PubMed ID: 27899251
[TBL] [Abstract][Full Text] [Related]
8. Docosahexaenoic acid inhibits the invasion of MDA-MB-231 breast cancer cells through upregulation of cytokeratin-1.
Blanckaert V; Kerviel V; Lépinay A; Joubert-Durigneux V; Hondermarck H; Chénais B
Int J Oncol; 2015; 46(6):2649-55. PubMed ID: 25825023
[TBL] [Abstract][Full Text] [Related]
9. Identification Keratin 1 as a cDDP-resistant protein in nasopharyngeal carcinoma cell lines.
Tang S; Huang W; Zhong M; Yin L; Jiang H; Hou S; Gan P; Yuan Y
J Proteomics; 2012 Apr; 75(8):2352-60. PubMed ID: 22348822
[TBL] [Abstract][Full Text] [Related]
10. Decoration of polymeric micelles with cancer-specific peptide ligands for active targeting of paclitaxel.
Shahin M; Ahmed S; Kaur K; Lavasanifar A
Biomaterials; 2011 Aug; 32(22):5123-33. PubMed ID: 21501865
[TBL] [Abstract][Full Text] [Related]
11. Landscape phages and their fusion proteins targeted to breast cancer cells.
Fagbohun OA; Bedi D; Grabchenko NI; Deinnocentes PA; Bird RC; Petrenko VA
Protein Eng Des Sel; 2012 Jun; 25(6):271-83. PubMed ID: 22490956
[TBL] [Abstract][Full Text] [Related]
12. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
Zhang YH; Li G; Yu J; Xu MS; Liu ZX
Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
[TBL] [Abstract][Full Text] [Related]
13. Peptide modified polymeric micelles specific for breast cancer cells.
Mathews AS; Ahmed S; Shahin M; Lavasanifar A; Kaur K
Bioconjug Chem; 2013 Apr; 24(4):560-70. PubMed ID: 23514428
[TBL] [Abstract][Full Text] [Related]
14. TKD peptide as a ligand targeting drug delivery systems to memHsp70-positive breast cancer.
Meng Y; Wang S; Li C; Qian M; Zheng Y; Yan X; Huang R
Int J Pharm; 2016 Feb; 498(1-2):40-8. PubMed ID: 26680317
[TBL] [Abstract][Full Text] [Related]
15. A targeted proteomics approach to the quantitative analysis of ERK/Bcl-2-mediated anti-apoptosis and multi-drug resistance in breast cancer.
Yang T; Xu F; Sheng Y; Zhang W; Chen Y
Anal Bioanal Chem; 2016 Oct; 408(26):7491-503. PubMed ID: 27510278
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
Menendez JA; Vellon L; Colomer R; Lupu R
Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
18. A safe, simple and efficient doxorubicin prodrug hybrid micelle for overcoming tumor multidrug resistance and targeting delivery.
Bao Y; Yin M; Hu X; Zhuang X; Sun Y; Guo Y; Tan S; Zhang Z
J Control Release; 2016 Aug; 235():182-194. PubMed ID: 27264552
[TBL] [Abstract][Full Text] [Related]
19. Sequence diversity in the lasso peptide framework: discovery of functional microcin J25 variants with multiple amino acid substitutions.
Pan SJ; Link AJ
J Am Chem Soc; 2011 Apr; 133(13):5016-23. PubMed ID: 21391585
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of the breast cancer cell-binding peptide, p160.
Askoxylakis V; Zitzmann S; Mier W; Graham K; Krämer S; von Wegner F; Fink RH; Schwab M; Eisenhut M; Haberkorn U
Clin Cancer Res; 2005 Sep; 11(18):6705-12. PubMed ID: 16166451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
